Predicting heart injury after laparoscopic tumor removal
Risk Identification and Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/Paraganglioma Resection:A Ambispective Cohort Study.
This study looks at patients having laparoscopic surgery for certain tumors to see what factors might lead to heart injury afterwards and to create a way to predict these risks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05752773 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients undergoing elective laparoscopic resection of pheochromocytoma and paraganglioma. It aims to identify risk factors for myocardial injury following the procedure and to develop a predictive model for such injuries. The study will enroll 700 patients, combining retrospective and prospective data, and will analyze vital signs and other factors to enhance the prediction accuracy. Participants will be monitored for 30 days post-surgery without any additional interventions.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for laparoscopic resection of pheochromocytoma or paraganglioma.
Not a fit: Patients with a history of congenital heart disease, prior cardiac surgery, or elevated troponin levels prior to surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction and prevention of myocardial injury in patients undergoing laparoscopic tumor resections.
How similar studies have performed: While similar predictive models have been explored, this specific approach to myocardial injury prediction in laparoscopic tumor resections is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled for Laparoscopic PPGL resection Exclusion Criteria: 1. Open or laparoscopic conversion to open PPGL resection was excluded 2. Cardiac paraganglioma was excluded 3. History of congenital heart disease or cardiac surgery was excluded 4. Patients with preoperative troponin/hypersensitive troponin elevation were excluded 5. Carotid body tumor and accessory ganglioma of jugular tympanum without endocrine function were excluded
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Ling Lan, Md — Peking Union Medical College Hospital
- Study coordinator: Ling Lan, Md
- Email: lanling_1988@163.com
- Phone: +86-18515311407
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.